Y. Y. Janjigian Et Al. , "Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. 2023. Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (Barcelona, Spain).
Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J., ... Weber, P. E. Y.(2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain
Janjigian, Y. Et Al. "Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. "Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Janjigian, Y. Y. Et Al. (2023) . "Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain.
@conferencepaper{conferencepaper, author={Y. Y. Janjigian Et Al. }, title={Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={Barcelona}, country={Spain}, year={2023}}